EVI1 expression in acute myeloid leukaemia

被引:51
作者
Langabeer, SE
Rogers, JR
Harrison, G
Wheatley, K
Walker, H
Bain, BJ
Burnett, AK
Goldstone, AH
Linch, DC
Grimwade, D
机构
[1] UCL, Sch Med, Dept Haematol, London WC1E 6HX, England
[2] UCL Hosp, Dept Haematol, London, England
[3] Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England
[4] Univ Birmingham, Clin Trials Unit, Birmingham, W Midlands, England
[5] St Marys Hosp, Imperial Coll, Sch Med, Dept Haematol, London, England
[6] Cardiff Univ, Dept Haematol, Cardiff CF4 4XN, S Glam, Wales
[7] Guys Hosp, Guys Kings & St Thomas Sch Med, Div Med & Mol Genet, London SE1 9RT, England
关键词
AML; APL; EVI1; 3q26; clinical trials;
D O I
10.1046/j.1365-2141.2001.02569.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute myeloid leukaemia (AML) with 3q26 cytogenetic abnormalities is associated with overexpression of EVI1, dysmegakaryopoiesis and poor prognosis. Screening for EVI1 transcripts was performed in 336 cases of AML, including 139 patients with acute promyelocytic leukaemia (APL). Expression was detected in 7 out of 10 cases with and 23 out of 326 without 3q26 abnormalities including one APL case. Among cases lacking 3q abnormalities, detection of EVI1 transcripts was neither associated with characteristic dysmegakaryopoietic features, nor predictive of a poor outcome, indicating that screening will probably not assist in treatment stratification. This study nevertheless demonstrates that deregulation of EVI1, although rare in APL, is a relatively frequent event in AML.
引用
收藏
页码:208 / 211
页数:4
相关论文
共 10 条
[1]   Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid:: Result of the randomized MRC trial [J].
Burnett, AK ;
Grimwade, D ;
Solomon, E ;
Wheatley, K ;
Goldstone, AH .
BLOOD, 1999, 93 (12) :4131-4143
[2]   Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: A model for human AML [J].
Cuenco, GM ;
Nucifora, G ;
Ren, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1760-1765
[3]   The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].
Grimwade, D ;
Walker, H ;
Oliver, F ;
Wheatley, K ;
Harrison, C ;
Harrison, G ;
Rees, J ;
Hann, I ;
Stevens, R ;
Burnett, A ;
Goldstone, A .
BLOOD, 1998, 92 (07) :2322-2333
[4]   Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials [J].
Langabeer, SE ;
Walker, H ;
Rogers, JR ;
Burnett, AK ;
Wheatley, K ;
Swirsky, D ;
Goldstone, AH ;
Linch, DC .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (04) :925-928
[5]  
Mitelman F., 1995, SUPPLEMENT INT SYSTE
[6]   The EVI1 gene in myeloid leukemia [J].
Nucifora, G .
LEUKEMIA, 1997, 11 (12) :2022-2031
[7]   EXPRESSION OF EVI1 IN MYELODYSPLASTIC SYNDROMES AND OTHER HEMATOLOGIC MALIGNANCIES WITHOUT 3Q26 TRANSLOCATIONS [J].
RUSSELL, M ;
LIST, A ;
GREENBERG, P ;
WOODWARD, S ;
GLINSMANN, B ;
PARGANAS, E ;
IHLE, J ;
TAETLE, R .
BLOOD, 1994, 84 (04) :1243-1248
[8]   ABNORMALITIES OF 3Q21 AND 3Q26 IN MYELOID MALIGNANCY - A UNITED-KINGDOM CANCER CYTOGENETIC GROUP-STUDY [J].
SECKERWALKER, LM ;
MEHTA, A ;
BAIN, B .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (02) :490-501
[9]   Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements [J].
Sitailo, S ;
Sood, R ;
Barton, K ;
Nucifora, C .
LEUKEMIA, 1999, 13 (11) :1639-1645
[10]   Expression of the Zn finger gene, EVI-1, in acute promyelocytic leukemia [J].
Xi, ZF ;
Russell, M ;
Woodward, S ;
Thompson, F ;
Wagner, L ;
Taetle, R .
LEUKEMIA, 1997, 11 (02) :212-220